imatinib mesylate has been researched along with Fusiform Aneurysm in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adam, MP; Albert, CM; Amiel, J; Beck, AE; Bhoj, EJ; Bly, RA; Boos, MD; Chang, I; Chenbhanich, J; Christodoulou, J; Curry, C; Dahl, JP; Dobyns, WB; Everman, D; Ganapathi, S; Guimier, A; Gupta, D; Hakonarson, H; Heike, CL; Li, D; Miller, DE; Park, J; Perkins, JA; Shieh, J; Sun, A; Webster, R; Wenger, TL; Wilson, M; Wu, N; Zackai, EH; Zarate, YA | 1 |
1 other study(ies) available for imatinib mesylate and Fusiform Aneurysm
| Article | Year |
|---|---|
Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
Topics: Adolescent; Adult; Aneurysm; Child; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Infant; Leukoencephalopathies; Male; Myofibromatosis; Pedigree; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta | 2020 |